3D Systems Corporation DDD

3D Systems Corp provide comprehensive 3D printing and digital manufacturing solutions, including 3D printers for plastics and metals, materials, software, and services, including maintenance, manufacturing and applications engineering. Its solutions support applications in two key industry verticals: Healthcare Solutions provide surgical planning, implants, instrumentation, and medical education solutions to help medical device manufacturers and healthcare providers accelerate, and ultimately, transform healthcare, and Industrial Solutions which includes aerospace, defense, transportation and general manufacturing. The company operates in the Americas, EMEA, and APAC regions.

DDD hizo una división de acciones (split) de 3:2 el 25 de febrero de 2013: cada 2 acciones se convirtieron en 3. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 2 sept

  Why Is 3D Systems (DDD) Down 7.6% Since Last Earnings Report?

  3D Systems (DDD) reported Q2 2026 earnings that beat consensus estimates with a narrower loss of 4 cents per share versus 6 cents year-ago. Revenues of $94.6M slightly exceeded expectations, driven by double-digit growth in metal and polymer printer systems. Healthcare Solutions became the largest segment with 6.8% growth, while Industrial Solutions declined 6.7%. Gross margins contracted 170 bps due to printer sales mix and pricing pressures. The company issued Q3 guidance of $96-99M in revenues and projects continued momentum from new printer launches.

  

• GlobeNewswire Inc. 27 ago

  Correction: Bioprinting Market to Reach $5.1 Billion by 2030, Driven by Regenerative Medicine Demand and AI Integration

  The global bioprinting market is projected to grow from $2.1 billion in 2024 to $5.1 billion by 2030 at a 16.1% CAGR, driven by regenerative medicine demand, pharmaceutical adoption for drug discovery, reduced animal testing, and AI integration. North America leads with 38% market share, while emerging technologies like 4D bioprinting and organ-on-chip devices expand market boundaries.

  

• GlobeNewswire Inc. 25 ago

  AI-Driven Bioprinting Emerges as a High-Conviction Investment Theme as Corporate AI Spending Surpasses $252 Billion

  AI investment in bioprinting has reached a historic inflection point with corporate AI spending totaling $252.3 billion in 2024. The U.S. leads global AI investment with $109.1 billion, enabling faster commercialization of AI-integrated bioprinting technologies. Major venture capital rounds validate the sector, with companies developing AI-powered tissue therapies for drug discovery, regenerative medicine, and personalized treatments. The competitive landscape is intensifying with key players securing significant funding and strategic pharma partnerships.

  

• GlobeNewswire Inc. 23 jul

  3D Systems Announces Date of Second Quarter 2026 Financial Results

  3D Systems (NYSE: DDD) announced it will release its second quarter 2026 financial results on August 3, 2026, followed by a conference call and webcast on August 4, 2026 at 8:30 a.m. Eastern Time to discuss the results.